01 / CARRIER
Nanostructured lipid carriers
Exploration of solid/liquid lipid matrices for small-molecule payloads, with attention to solubility, crystallization, loading and controlled release.
LusoNano · Technology & research pipeline
Engineering delivery.
Investigating immune response.
A preclinical research framework for functionalized lipid nanocarriers, cell-selective oncology delivery and rational combination therapeutics.
Technology platform
Surface chemistry meets tumor biology.
Our research concepts examine how lipid matrix composition, stealth coatings, and receptor-directed surface ligands may influence payload retention, biodistribution and cellular exposure. Specific performance characteristics remain to be established experimentally.
02 / SURFACE
Functionalized interfaces
Investigation of polysarcosine-based surface coatings and ligand-conjugated lipids for selective biological recognition.
03 / TARGET
Cell-specific delivery
Receptor and microenvironment targeting concepts across tumor cells, myeloid populations, stromal fibroblasts and mineralized bone.
Exploratory research pipeline
Programs organized by biological compartment.
The following are research directions and hypotheses, not claims of validated products, completed studies or clinical-stage assets.
Discovery concept
Tumor cellsTumor-selective pathway modulation
Explore ligand-directed delivery to malignant cells and effects on hypoxia adaptation, inflammatory signaling, resistance pathways and immunotherapy response.
Discovery concept
Myeloid cellsTAM and myeloid microenvironment modulation
Evaluate selective delivery to immunosuppressive macrophage subsets, including CD206-associated recognition, and assess effects on macrophage survival and T-cell suppression.
Discovery concept
FibroblastsCAF phenotype and immune exclusion
Investigate FAP-associated delivery and complementary modulation of TGF-β signaling, oxidative pathways and fibroblast differentiation to assess whether immune-excluding stroma can be normalized.
Discovery concept
Bone nicheBone-localized oncology delivery
Explore mineral-affinity ligands as a means of enriching drug carriers at bone surfaces, with special attention to release into adjacent metastatic marrow tissue.
Research framework
CombinationsNanomedicine-enabled immunotherapy combinations
Study whether selective pathway modulation can complement checkpoint blockade or cellular immunotherapy while preserving beneficial immune-cell function.
Preclinical validation
Mechanism before claims.
Each research concept calls for analytical characterization and biologically relevant comparison against free drug and nonfunctionalized carriers.
Priority measurements include drug loading and stability, receptor specificity, cellular uptake versus intracellular drug exposure, tissue distribution, target engagement and immune functional outcomes.
FormulationParticle size, dispersity, lipid compatibility, loading and release
↓
TargetingReceptor-dependent uptake and off-target comparison
↓
Biological activityTarget engagement, phenotype and T-cell function
↓
TranslationExposure, safety, manufacturability and model limitations
Research concepts only. No human therapeutic claims, investigational products for sale, or clinical services are represented on this page.
Illustrative imagery · preclinical research
Research environment
Precision science, from concept to preclinical evaluation.
Illustrative imagery; not photographs of LusoNano facilities or personnel.